阿托伐他汀钙联合硫普罗宁治疗非酒精性脂肪肝60例分析

Atorvastatin calcium with tiopronin in treatment of 60 cases of nonalcoholic fatty liver disease

目的观察阿托伐他汀钙联合硫普罗宁治疗非酒精性脂肪肝的临床治疗效果。方法选择我院2011年1月～2012年12月期间收治的120例非酒精性脂肪肝患者随机分为观察组和对照组各60例。对照组患者行复方甘草酸苷胶囊治疗，观察组患者行阿托伐他汀钙联合硫普罗宁治疗。分别观察两组患者的临床治疗效果，并对比分析两组患者治疗前后患者血清酶（ALT、AST、GGT）和血脂（TG、TC）指标变化情况，同时观察并统计两组患者不良反应的发生率。结果观察组患者临床治疗的总有效率为83．3％，对照组为51．6％，差异有统计学意义（P〈0．01）。治疗后，观察组患者ALT、AST、GGT及TG、TC指标较治疗前显著下降（P〈0．01），对照组患者各指标较治疗前有所下降（P〈0．05）。在组间比较上，治疗后观察组患者各指标的下降幅度要大于对照组（P〈0．05）。观察组患者头晕乏力、恶心呕吐、腹胀腹泻、食欲下降不良反应的总发生率为16．66％，对照组患者为16．68％，差异无统计学意义（P〉0．05）。结论阿托伐他汀钙联合硫普罗宁治疗非酒精性脂肪肝的临床疗效显著，且不良反应少，值得推广与应用。

Objective To observe the clinical treatment effect of atorvastatin calcium with tiopmnin in treatment of nonalcoholic fatty liver disease. Methods The 120 patients with nonalcoholic fatty liver disease admitted in our hospital from January 2011 to December 2012 were randomly divided into two groups： the observation group of 60 cases and control group of 60 cases. Control group patients with compound glycyrrhizic acid,glycosides capsules observation group of patients with atorvastatin calcium with tiopronin the clinical therapeutic effect of two groups patients respectively, and contrast analysis of two groups before and after treatment in patients serum enzymes （ALT, AST, GGT） and blood lipids （TG, TC） index changes, at the same time observation and statistics of two groups patients the incidence of adverse reactions were compared. Results The observation group of patients clinical total effective rate was 83.3%, control group was 51.6%, there was significant difference （P 〈 0.01）. After treatment, the observation group of patients ALT, AST, GGT and TG, TC index significantly decreased than before treatment （P 〈 0.01）, the index in the control group patients decreased than before treatment （P 〈 0.05）. Comparisons between the groups, the index of the observation group of patients after treatment decreased than the control group （P 〈 0.05）. Observation group of patients with dizziness, fatigue, nausea, vomiting, abdominal distension diarrhoea, appetite to drop the total incidence of a＆ verse reactions was 16.66%. Control group patients was 16.68%. Comparison of two groups, there was no statistically significant difference （P 〉 0.05）. Conclusion The clinical curative effect of atorvastatin calcium with tiopronin in treatment of nonalcoholic fatty liver disease is distinct, and has less adverse reactions, is worthy of popularization and application.